Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above?
Publication
, Journal Article
Califf, RM
Published in: JAMA
April 5, 2006
Duke Scholars
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
April 5, 2006
Volume
295
Issue
13
Start / End Page
1579 / 1580
Location
United States
Related Subject Headings
- Polysaccharides
- Myocardial Infarction
- Humans
- General & Internal Medicine
- Fondaparinux
- Factor X
- Anticoagulants
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Califf, R. M. (2006). Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? JAMA, 295(13), 1579–1580. https://doi.org/10.1001/jama.295.13.jed60020
Califf, Robert M. “Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above?” JAMA 295, no. 13 (April 5, 2006): 1579–80. https://doi.org/10.1001/jama.295.13.jed60020.
Califf RM. Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? JAMA. 2006 Apr 5;295(13):1579–80.
Califf, Robert M. “Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above?” JAMA, vol. 295, no. 13, Apr. 2006, pp. 1579–80. Pubmed, doi:10.1001/jama.295.13.jed60020.
Califf RM. Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? JAMA. 2006 Apr 5;295(13):1579–1580.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
April 5, 2006
Volume
295
Issue
13
Start / End Page
1579 / 1580
Location
United States
Related Subject Headings
- Polysaccharides
- Myocardial Infarction
- Humans
- General & Internal Medicine
- Fondaparinux
- Factor X
- Anticoagulants
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences